Literature DB >> 11089522

A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1.

B A Scaglione-Sewell1, M Bissonnette, S Skarosi, C Abraham, T A Brasitus.   

Abstract

Previous studies by our laboratory have shown that a noncalcemic fluorinated analog of 1alpha,25-dihydroxyvitamin D3, 1alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholcal ciferol (F6-D3), significantly reduced the frequency of colonic adenomas and completely abolished the development of colonic adenocarcinomas in rats treated with azoxymethane. The mechanisms involved in this analog's chemopreventive actions, however, remain unclear. In the present study, we now show that although both 1alpha,25-dihydroxyvitamin D3 and F6-D3 inhibited the proliferation of CaCo-2 cells, a human colonic adenocarcinoma cell line, by increasing their doubling times, only F6-D3 caused an arrest of these cells in the G1 phase of their cell cycle. This arrest was accompanied by an increase in the expression of the cyclin-dependent kinase (cdk) inhibitor proteins, p2Waf1 and p27Kip1, which served to decrease the activity of cyclin-dependent kinase 2 and cyclin-dependent kinase 6, whereas the expression and phosphorylation of pRB were unchanged. In contrast to the increased expression of these cdk inhibitors, the expression of cyclin E was decreased, which further inhibited the activity of cyclin-dependent kinase 2. Collectively, the inhibition of these cyclin-dependent kinases served to arrest the CaCo-2 cells, independent of changes in pRB. Furthermore, antibody neutralization studies suggest that transforming growth factor-beta may mediate the coassociations between cdk2 and p27Kip1 and cyclin E induced by F6-D3. These data indicate that cell cycle arrest may, at least in part, underlie the chemopreventive actions of F6-D3 observed in the azoxymethane model of colon cancer. Furthermore, if the antiproliferative action observed in CaCo-2 cells also occurs in human colonic epithelium, F6-D3 may have chemopreventive potential against human colon cancer, as well.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11089522     DOI: 10.1210/endo.141.11.7782

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  30 in total

1.  Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.

Authors:  Kimmie Ng; Daniel J Sargent; Richard M Goldberg; Jeffrey A Meyerhardt; Erin M Green; Henry C Pitot; Bruce W Hollis; Michael N Pollak; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

Review 2.  The role of vitamin D in hepatic metastases from colorectal cancer.

Authors:  E Shaw; N Massaro; N T Brockton
Journal:  Clin Transl Oncol       Date:  2017-08-11       Impact factor: 3.405

Review 3.  Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence.

Authors:  Ruoxu Dou; Kimmie Ng; Edward L Giovannucci; JoAnn E Manson; Zhi Rong Qian; Shuji Ogino
Journal:  Br J Nutr       Date:  2016-05       Impact factor: 3.718

4.  Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer.

Authors:  Chen Yuan; Lindsay Renfro; Pratibha B Ambadwar; Fang-Shu Ou; Howard L McLeod; Federico Innocenti; Jeffrey A Meyerhardt; Brian M Wolpin; Richard M Goldberg; Axel Grothey; Charles S Fuchs; Kimmie Ng
Journal:  Cancer Causes Control       Date:  2019-05-18       Impact factor: 2.506

5.  Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).

Authors:  Jeffrey A Meyerhardt; Kimmie Ng; Chen Yuan; Kaori Sato; Bruce W Hollis; Sui Zhang; Donna Niedzwiecki; Fang-Shu Ou; I-Wen Chang; Bert H O'Neil; Federico Innocenti; Heinz-Josef Lenz; Charles D Blanke; Richard M Goldberg; Alan P Venook; Robert J Mayer; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531

6.  Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity.

Authors:  Songcang Chen; Christopher S Law; David G Gardner
Journal:  J Steroid Biochem Mol Biol       Date:  2009-12-02       Impact factor: 4.292

7.  1,25-dihydroxyvitamin D regulation of glucose metabolism in Harvey-ras transformed MCF10A human breast epithelial cells.

Authors:  Wei Zheng; Fariba Tayyari; G A Nagana Gowda; Daniel Raftery; Eric S McLamore; Jin Shi; D Marshall Porterfield; Shawn S Donkin; Brian Bequette; Dorothy Teegarden
Journal:  J Steroid Biochem Mol Biol       Date:  2013-04-22       Impact factor: 4.292

Review 8.  Vitamin D and Physical Activity in Patients With Colorectal Cancer: Epidemiological Evidence and Therapeutic Implications.

Authors:  Vicente Morales-Oyarvide; Jeffrey A Meyerhardt; Kimmie Ng
Journal:  Cancer J       Date:  2016 May-Jun       Impact factor: 3.360

9.  Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial.

Authors:  Veronika Fedirko; Roberd M Bostick; W Dana Flanders; Qi Long; Eduard Sidelnikov; Aasma Shaukat; Carrie R Daniel; Robin E Rutherford; Jill Joelle Woodard
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

10.  Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer.

Authors:  K Ng; B M Wolpin; J A Meyerhardt; K Wu; A T Chan; B W Hollis; E L Giovannucci; M J Stampfer; W C Willett; C S Fuchs
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.